// App-Quantinova.ai

Filters

Biomarkers

No records found for your search

Conference Name

No records found for your search

Country

























Company

Search valid company name..

Conference Year













Drug











Disease

Medical Centers

Search valid medical center name..

Outcomes





Presenter

Search valid presenter name..

Principal Investigators

Search valid principal investigator name..

Phase










Patient Segments

Search valid patient segment..

Result



Sponsor

Search valid sponsor name..

Study ID

Search your valid Study ID..

Therapeutic Area
























45280 Abstracts

CHARACTERISTICS AND OUTCOMES OF PATIENTS WITH ACUTE MYELOID LEUKAEMIA TREATED WITH VENETOCLAX COMBINATION THERAPY: REAL-WORLD EXPERIENCE IN BOTH FRONTLINE AND RELAPSED/REFRACTORY SETTINGS

Ho Pui Jeff Lam - European Hematology Association (EHA) , 2022

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Acute myelocytic leukemia

Venetoclax

EXPLORING ALTERNATIVE DOSING REGIMENS OF SINGLE-AGENT BELANTAMAB MAFODOTIN ON SAFETY AND EFFICACY IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA: DREAMM-14

Malin Hultcrantz - European Hematology Association (EHA) , 2022

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Multiple Myeloma

GSK2857916

A 9 YEAR REVIEW OF BLOOD TRANSFUSION PRACTICE AND ADHERENCE TO NICE GUIDELINES AT A DISTRICT GENERAL HOSPITAL, UK

Natalie Clayden - European Hematology Association (EHA) , 2022

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

IMPAIRMENT OF TCR SIGNALLING IN PATIENTS WITH MYELOFIBROSIS TREATED WITH RUXOLITINIB

Patrick Harrington - European Hematology Association (EHA) , 2022

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Myelofibrosis

Ruxolitinib phosphate

PIRTOBRUTINIB, A HIGHLY SELECTIVE, NON-COVALENT (REVERSIBLE) BTK INHIBITOR IN PREVIOUSLY TREATED CLL/SLL: UPDATED RESULTS FROM THE PHASE 1/2 BRUIN STUDY

Anthony R. Mato - European Hematology Association (EHA) , 2022

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

DNA DAMAGE TRIGGERS A P53 INDUCED AGEING RESPONSE IN HAEMATOPOIETIC STEM CELLS

Meng Wang - European Hematology Association (EHA) , 2022

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

COMORBIDITIES AND COMPLICATIONS ACROSS GENOTYPES IN ADULT PATIENTS WITH PYRUVATE KINASE DEFICIENCY: ANALYSIS FROM THE PEAK REGISTRY

Andreas Glenthj - European Hematology Association (EHA) , 2022

Therapeutic Area

Disease

Drug/Treatment

Genetic Disorder

Pyruvate kinase (PK) deficiency

N/A

PRE-HAEMATOPOIETIC STEM CELL TRANSPLANT DENTAL ASSESSMENT: A SERVICE EVALUATION

Rana Wali - European Hematology Association (EHA) , 2022

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

MODELLING AND TARGETING ACUTE MYELOID LEUKAEMIA CELLS IN THE BONE MARROW PROTECTIVE NICHE

Eleni E Ladikou - European Hematology Association (EHA) , 2022

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Acute myelocytic leukemia

Natalizumab

MANIFEST-2, A GLOBAL, PHASE 3, RANDOMIZED, DOUBLE-BLIND, ACTIVE-CONTROL STUDY OF PELABRESIB (CPI-0610) AND RUXOLITINIB VS PLACEBO AND RUXOLITINIB IN JAK INHIBITOR-NAÏVE MYELOFIBROSIS PATIENTS

Claire Harrison - European Hematology Association (EHA) , 2022

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Myelofibrosis

Ruxolitinib phosphate

NPM1 MUTATED AML: IMPACT OF CO-MUTATIONAL PATTERNS - RESULTS OF THE EUROPEAN HARMONY ALLIANCE

Alberto Hernndez-Snchez - European Hematology Association (EHA) , 2022

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

OUTCOMES FOLLOWING TREATMENT WITH A COVALENT BTK AND BCL2 INHIBITOR AMONG PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)/SMALL LYMPHOCYTIC LYMPHOMA (SLL): A REAL-WORLD STUDY OF A LARGE U.S. DATABASE

Toby A Eyre - European Hematology Association (EHA) , 2022

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Chronic Lymphocytic Leukemia

L-Tyrosine

THE ENDOSOMAL ADAPTOR PROTEIN MYCT1 CONTROLS ENVIRONMENTAL SENSING IN HUMAN HSCS

Julia Aguade-Gorgorio - European Hematology Association (EHA) , 2022

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

Dex-HEMA

A PHASE 4 STUDY OF FRACTIONATED GEMTUZUMAB OZOGAMICIN ON QT INTERVAL AND SAFETY IN PATIENTS WITH RELAPSED/REFRACTORY CD33-POSITIVE ACUTE MYELOID LEUKEMIA

Pau Montesinos - European Hematology Association (EHA) , 2022

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Hepatic veno-occlusive disease with immunodeficiency

Gemtuzumab ozogamicin

PIRTOBRUTINIB, A HIGHLY SELECTIVE, NON-COVALENT (REVERSIBLE) BTK INHIBITOR IN PREVIOUSLY TREATED MANTLE CELL LYMPHOMA: UPDATED RESULTS FROM THE PHASE 1/2 BRUIN STUDY

Paolo Ghia - European Hematology Association (EHA) , 2022

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Mantle cell lymphoma

N/A

INMIND: A PHASE 3 STUDY OF TAFASITAMAB PLUS LENALIDOMIDE AND RITUXIMAB VERSUS PLACEBO PLUS LENALIDOMIDE AND RITUXIMAB FOR RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA (FL) OR MARGINAL ZONE LYMPHOMA (MZL)

Laurie H. Sehn - European Hematology Association (EHA) , 2022

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Congestive heart failure

Lenalidomide

BETALUTIN® IN PATIENTS WITH RELAPSED/ REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL) NOT ELIGIBLE FOR AUTOLOGOUS STEM CELL TRANSPLANT

Timothy Illidge - European Hematology Association (EHA) , 2022

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Diffuse large B-cell lymphoma

Betalutin

EVALUATION OF CURRENT NATIONAL PRACTICE IN THE PREVENTION OF PTLD POST PAEDIATRIC HSCT

Eleanor Kissane - European Hematology Association (EHA) , 2022

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Post-transplant lymphoproliferative disorder

Rituximab

POST HOC ANALYSIS OF PATIENTS WITH HIGHLY PROLIFERATIVE VARIANTS OF MANTLE CELL LYMPHOMA TREATED WITH ACALABRUTINIB

Steven Le Gouill - European Hematology Association (EHA) , 2022

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Mantle cell lymphoma

ACP-196

SMALL EXTRACELLULAR VESICLES IN THE LEUKEMIA MICROENVIRONMENT SUSTAIN CLL PROGRESSION BY HAMPERING T CELL-MEDIATED ANTI-TUMOR IMMUNITY

Ernesto Gargiulo - European Hematology Association (EHA) , 2022

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

Copyright © 2026. QuantiNova All rights reserved